283.54
-2.47 (-0.86%)
| Previous Close | 286.01 |
| Volume | 5,014,775 |
| Price / Earnings (Forward) | 18.06 |
| Price / Sales | 7.86 |
| 52 Weeks Range | |
| TTM Dividend Yield | 3.18% |
| Profit Margin | 7.31% |
| Operating Margin (TTM) | 30.43% |
| Diluted EPS (TTM) | 2.35 |
| Quarterly Revenue Growth (YOY) | 8.40% |
| Quarterly Earnings Growth (YOY) | -6.10% |
| Total Debt/Equity (MRQ) | 4,789.60% |
| Current Ratio (MRQ) | 0.760 |
| Operating Cash Flow (TTM) | 16.40 B |
| Levered Free Cash Flow (TTM) | 16.94 B |
| Return on Assets (TTM) | 8.34% |
| Return on Equity (TTM) | 88.40% |
News Mood
-
How Did AbbVie's Neuroscience Franchise Perform in Q3?
3 days ago, 11:03AM
-
AbbVie (ABBV) Reports Positive Phase 3 QULIPTA Migraine Trial Results
12 Nov, 2:16AM
-
Can AbbVie (ABBV) Justify Its Valuation After Raised Guidance And Strong Results?
10 Nov, 11:00AM
AIStockmoo Score
| Value 30% | -3.2 |
| Dearer than its usual valuation. info | |
| Earns about its cost of capital. Returns on capital falling. info | |
| High debt. Strong profitability. Thin short-term liquidity. Positive cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | 3.2 |
| Uptrend over the past year. Trading near its 52-week high. info | |
| In an uptrend: the price is above its moving averages, and they are rising. It is close to them. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.8 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 0.9 |
| Insiders net selling recently. info | |
| Institutions net +1.39% of shares in their latest 13F filings: 2,143 holders increased, 1,888 decreased (quarter to 30 Sep 2026). info | |
| Market and sector conditions are neutral. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Earnings per share have mostly fallen. Earnings have been uneven. info | |
| Above its medium-term trend line. info | |
| Price is high against its 52-week average. Up over 5 years. info | |
| Short-term momentum fading. info | |
| Price is near support. info | |
| Final Score | 0.27 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
| Drug Manufacturers - General (Global) | Mixed | Bullish | |
| Stock | AbbVie Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| ABBV | - | 3.18% | - | - | 0.3 |
| NVO | 171 B | 29.67% | 9.82 | 5.27 | 0.0 |
| PFE | 157 B | 7.66% | 39.34 | 1.80 | 0.7 |
| BMY | 119 B | 4.23% | 12.94 | 5.20 | 1.4 |
| GSK | 96 B | 1.42% | 16.43 | 3.92 | -0.1 |
| JNJ | - | 1.92% | - | 8.05 | 1.1 |
Select this tab to load the latest available analysis.
|
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Large Value |
| % Held by Insiders | 0.10% |
| % Held by Institutions | 74.87% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| STEWART JEFFREY RYAN | - | 293.39 | -44,069 | -12,929,405 |
| Aggregate Net Quantity | -44,069 | |||
| Aggregate Net Value ($) | -12,929,405 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 293.39 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| STEWART JEFFREY RYAN | Officer | 12 Nov 2026 | Disposed (-) | 3,450 | 294.45 | 1,015,853 |
| STEWART JEFFREY RYAN | Officer | 09 Nov 2026 | Sell (-) | 40,619 | 293.30 | 11,913,553 |
| STEWART JEFFREY RYAN | Officer | 09 Nov 2026 | Option execute | 40,619 | - | - |
Institutions
Institutional ownership: 86.87%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 2,143 | 61,697,401 |
| Decreased | 1,888 | 42,902,084 |
| New | 224 | 8,979,063 |
| Sold out | 107 | 3,122,065 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
| Date | Type | Details |
|---|---|---|
| 19 Nov 2026 | Yahoo Finance |
Does AbbVie (ABBV) Need This New Solid Tumor Cancer Partnership?
AbbVie (NYSE:ABBV) and DISCO Pharmaceuticals announced a new collaboration to develop bispecific cancer therapies for solid tumors. The agreement focuses on applying DISCO Pharmaceuticals' proprietary bispecific technology platform to AbbVie's oncology research programs. The partnership is intended… |
| 19 Nov 2026 | Yahoo Finance |
AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics
The drugs developed through this collaboration will look to address significant unmet needs plaguing the solid tumour space. |
| 19 Nov 2026 | Yahoo Finance |
DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors
The collaboration leverages DISCO’s proprietary DISCOtech® surfaceome mapping platform and AND-gated bispecific discovery approach together with AbbVie’s global oncology research and development expertise to identify and potentially advance highly selective AND-gated bispecific therapeutics. Upon… |
| 17 Nov 2026 | Yahoo Finance |
How Did AbbVie's Neuroscience Franchise Perform in Q3?
ABBV's neuroscience franchise delivers 19.5% operational sales growth in Q3, prompting the company to raise its 2026 segment sales outlook to $13 billion. |
| 17 Nov 2026 | Yahoo Finance |
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
| 17 Nov 2026 | Yahoo Finance |
AbbVie Is Up 27% in a Year. Barclays Sees Another 14%
Key TakeawaysBarclays raised its AbbVie price target to $335 from $325 on Nov. 16 and kept its Overweight rating, after a run that has the stock up 27% in a year. |
| 16 Nov 2026 | Yahoo Finance |
AbbVie (ABBV) Expands Its Pipeline With New AI Drug Discovery Partnerships
AbbVie (NYSE:ABBV) has entered a new AI-driven drug discovery collaboration with Iambic to support its research pipeline. The pharmaceutical group is advancing its partnership with Brise Pharmaceuticals, gaining global development and commercialization rights for preclinical migraine programs.… |
| 16 Nov 2026 | Yahoo Finance |
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Launched Enchant® v3, a 41-billion-parameter transformer model for drug discovery and development, to drive decisions across our internal and partnership activitiesSigned AI discovery collaborations with Bayer and AbbVie; eight total partnerships signed since 2024Achieved a program milestone in… |
| 16 Nov 2026 | Yahoo Finance |
ETFs Are Net Sellers of AbbVie (ABBV) on Nov. 12
ETFs sold a net $62.0 million of AbbVie on Thursday, with 40 funds buying and 16 selling. |
| 14 Nov 2026 | Yahoo Finance |
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
These healthcare dividend stocks appeal to investors in different ways. |
| 13 Nov 2026 | Yahoo Finance |
AbbVie (ABBV) Stock Looks Below Fair Value After Strong Cash Flow Growth
AbbVie has delivered a strong share price run in recent years, and with the stock around US$295 the key question is how firmly its current market value rests on the cash it can generate over time. The stock has returned 203.1% over 5 years, which places substantial expectations into the price and… |
| 13 Nov 2026 | Yahoo Finance |
AbbVie or Johnson & Johnson: Only One Gets My Dividend Dollars for the Next 20 Years
Key TakeawaysAbbVie raised its quarterly dividend 5% on Oct. 30, while Johnson & Johnson took a $5… |
| 12 Nov 2026 | Yahoo Finance |
3 Pharmaceutical Stocks That Offer Safety and Growth
AbbVie, Merck and Gilead Sciences offer growing dividends alongside pipeline-driven growth, making pharmaceutical stocks a defensive option as investors seek shelter from market volatility. |
| 12 Nov 2026 | Yahoo Finance |
How Did AbbVie's Immunology Franchise Fare in Q3?
ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's decline. |
| 12 Nov 2026 | Yahoo Finance |
AbbVie Deal Altering The Investment Case For Nxera Pharma Stock (TSE:4565)?
Nxera Pharma announced in early November 2026 that its UK subsidiary entered an exclusive global license agreement with AbbVie for the EP4 agonist program in inflammatory bowel disease. The agreement includes a US$100 million upfront payment and potential milestones up to US$1.37 billion, plus… |
| 12 Nov 2026 | Yahoo Finance |
The Zacks Analyst Blog Highlights NVIDIA, Walmart, AbbVie, Pioneer Bancorp and Aspira
NVDA, WMT and ABBV headline Zacks' latest research, with growth drivers and business risks shaping their investment outlooks. |
| 12 Nov 2026 | Yahoo Finance |
Coca-Cola or AbbVie: The One Dividend Stock I’d Hold for the Next 20 Years
Key TakeawaysAbbVie raised its quarterly dividend 5. 2% to $1… |
| 12 Nov 2026 | Yahoo Finance |
AbbVie (ABBV) Reports Positive Phase 3 QULIPTA Migraine Trial Results
AbbVie (NYSE:ABBV) reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention against topiramate. The TEMPLE study found QULIPTA achieved superior tolerability compared with topiramate in adults with migraine. QULIPTA also showed better efficacy than topiramate on key… |
| 11 Nov 2026 | Yahoo Finance |
Top Analyst Reports for NVIDIA, Walmart & AbbVie
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Walmart Inc. (WMT), AbbVie Inc. (ABBV) as well as two micro-cap stocks, Pioneer Bancorp, Inc. (PBFS) and Aspira Women's Health Inc. (AWHL). |
| 11 Nov 2026 | Yahoo Finance |
ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?
AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges. |
| 11 Nov 2026 | Yahoo Finance |
3 Legacy Health Care Dividend Stocks That Never Go Out of Style
Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsuits, one plans a spinoff, and one raises its payout by a single cent. |
| 10 Nov 2026 | Yahoo Finance |
Can AbbVie (ABBV) Justify Its Valuation After Raised Guidance And Strong Results?
AbbVie (ABBV) just raised its full year 2026 revenue guidance to about US$67.8b and lifted its dividend, after reporting third quarter sales of US$17.4b and net income of US$4.2b. Recent price action has been strong, with AbbVie’s share price delivering a 6.1% 1 month gain and a 17.3% 3 month share… |
| Show more | ||
| TTM Dividend Yield | 3.18% |
| 5Y Average Dividend Yield | 3.22% |
| Payout Ratio | 268.80% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 15 Apr 2025 | 13 Feb 2025 | 15 May 2025 | 1.64 Cash |
| 15 Jan 2025 | 30 Oct 2024 | 14 Feb 2025 | 1.64 Cash |
| 15 Oct 2024 | 06 Sep 2024 | 15 Nov 2024 | 1.55 Cash |
| 15 Jul 2024 | 20 Jun 2024 | 15 Aug 2024 | 1.55 Cash |
| 12 Apr 2024 | 15 Feb 2024 | 15 May 2024 | 1.55 Cash |
| 12 Jan 2024 | 27 Oct 2023 | 15 Feb 2024 | 1.55 Cash |
| 12 Oct 2023 | 08 Sep 2023 | 15 Nov 2023 | 1.48 Cash |
| 13 Jul 2023 | 22 Jun 2023 | 15 Aug 2023 | 1.48 Cash |
| 13 Apr 2023 | 16 Feb 2023 | 15 May 2023 | 1.48 Cash |
| 12 Jan 2023 | 28 Oct 2022 | 15 Feb 2023 | 1.48 Cash |
| 13 Oct 2022 | 09 Sep 2022 | 15 Nov 2022 | 1.41 Cash |
| 14 Jul 2022 | 23 Jun 2022 | 15 Aug 2022 | 1.41 Cash |
| 13 Apr 2022 | 17 Feb 2022 | 16 May 2022 | 1.41 Cash |
| 13 Jan 2022 | 29 Oct 2021 | 15 Feb 2022 | 1.41 Cash |
| 14 Oct 2021 | 10 Sep 2021 | 15 Nov 2021 | 1.3 Cash |
| 14 Jul 2021 | 17 Jun 2021 | 16 Aug 2021 | 1.3 Cash |
| 14 Apr 2021 | 18 Feb 2021 | 14 May 2021 | 1.3 Cash |
| 14 Jan 2021 | 30 Oct 2020 | 16 Feb 2021 | 1.3 Cash |
| 14 Oct 2020 | 11 Sep 2020 | 16 Nov 2020 | 1.18 Cash |
| 14 Jul 2020 | 17 Jun 2020 | 14 Aug 2020 | 1.18 Cash |
| 14 Apr 2020 | 20 Feb 2020 | 15 May 2020 | 1.18 Cash |
| 14 Jan 2020 | 01 Nov 2019 | 14 Feb 2020 | 1.18 Cash |
| 11 Oct 2019 | 06 Sep 2019 | 15 Nov 2019 | 1.07 Cash |
| 12 Jul 2019 | 21 Jun 2019 | 15 Aug 2019 | 1.07 Cash |
| 12 Apr 2019 | 22 Feb 2019 | 15 May 2019 | 1.07 Cash |
| 14 Jan 2019 | 02 Nov 2018 | 15 Feb 2019 | 1.07 Cash |
| 12 Oct 2018 | 08 Sep 2018 | 15 Nov 2018 | 0.96 Cash |
| 12 Jul 2018 | 15 Jun 2018 | 15 Aug 2018 | 0.96 Cash |
| 12 Apr 2018 | 15 Feb 2018 | 15 May 2018 | 0.96 Cash |
| 11 Jan 2018 | 27 Oct 2017 | 15 Feb 2018 | 0.71 Cash |
| 12 Oct 2017 | 08 Sep 2017 | 15 Nov 2017 | 0.64 Cash |
| 12 Jul 2017 | 22 Jun 2017 | 15 Aug 2017 | 0.64 Cash |
| 11 Apr 2017 | 16 Feb 2017 | 15 May 2017 | 0.64 Cash |
| 11 Jan 2017 | 28 Oct 2016 | 15 Feb 2017 | 0.64 Cash |
| 12 Oct 2016 | 09 Sep 2016 | 15 Nov 2016 | 0.57 Cash |
| 13 Jul 2016 | 16 Jun 2016 | 15 Aug 2016 | 0.57 Cash |
| 13 Apr 2016 | 18 Feb 2016 | 16 May 2016 | 0.57 Cash |
| 13 Jan 2016 | 30 Oct 2015 | 16 Feb 2016 | 0.57 Cash |
| 13 Oct 2015 | 11 Sep 2015 | 16 Nov 2015 | 0.51 Cash |
| 13 Jul 2015 | 18 Jun 2015 | 14 Aug 2015 | 0.51 Cash |
| 13 Apr 2015 | 19 Feb 2015 | 15 May 2015 | 0.51 Cash |
| 13 Jan 2015 | 20 Oct 2014 | 13 Feb 2015 | 0.49 Cash |
| 10 Oct 2014 | 19 Sep 2014 | 17 Nov 2014 | 0.42 Cash |
| 11 Jul 2014 | 19 Jun 2014 | 15 Aug 2014 | 0.42 Cash |
| 11 Apr 2014 | 20 Feb 2014 | 15 May 2014 | 0.42 Cash |
| 13 Jan 2014 | 12 Dec 2013 | 14 Feb 2014 | 0.4 Cash |
| 10 Oct 2013 | 19 Sep 2013 | 15 Nov 2013 | 0.4 Cash |
| 11 Jul 2013 | 20 Jun 2013 | 15 Aug 2013 | 0.4 Cash |
| 11 Apr 2013 | 15 Feb 2013 | 15 May 2013 | 0.4 Cash |
| 11 Jan 2013 | 04 Jan 2013 | 15 Feb 2013 | 0.4 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 3.28 | 2 | 1.44 |
| 2024 | 6.20 | 4 | 3.49 |
| 2023 | 5.92 | 4 | 3.82 |
| 2022 | 5.64 | 4 | 3.49 |
| 2021 | 5.20 | 4 | 3.84 |
| 2020 | 4.72 | 4 | 4.41 |
| 2019 | 4.28 | 4 | 4.83 |
| 2018 | 3.59 | 4 | 3.89 |
| 2017 | 2.56 | 4 | 2.65 |
| 2016 | 2.28 | 4 | 3.64 |
| 2015 | 2.02 | 4 | 3.41 |
| 2014 | 1.66 | 4 | 2.54 |
| 2013 | 1.60 | 4 | 3.03 |
| Show more | |||
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |